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mented with regional cerebral perfusion may provide better
cerebral protection than more conventional techniques.
Although the data presented by Pigula, Siewers, and
Nemoto are suggestive of adequate cerebral protection, we
still believe that core cooling to 18°C is the principal compo-
nent of our cerebral protection strategy. Further study is war-
ranted to ascertain the relative merits of regional cerebral per-
fusion versus hypothermia for cerebral protection during
aortic arch reconstruction in the neonate. 
Christopher A. Caldarone, MD
Douglas M. Behrendt, MD
Division of Cardiovascular Surgery
Children’s Hospital of Iowa
200 Hawkins Dr
Iowa City, IA 52242-1083
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Drug therapy before coronary artery operations
To the Editor:
We were greatly interested by the results of the IMAGE
trial,1 which suggests European patients are more susceptible
than US patients to aprotinin-induced vein graft occlusion.
This has prompted us to inquire whether our patients have a
European or US response to aprotinin.
We have used aprotinin in varying doses for patients under-
going redo operations or for those with recent aspirin inges-
tion. Table I describes our mortality rate in consecutive
patients undergoing coronary artery bypass grafting with or
without other procedures between 1993 and 1998; a dose-
dependent increase in mortality is evident. However, the indi-
cations for aprotinin are also very important risk factors for
perioperative mortality. Thus it may not be too surprising that
patients given aprotinin have a higher mortality rate. To clar-
ify this, we have further analyzed our data to take risk factors
for mortality into account.
The patients and model have been described in detail else-
where.2 Logistic regression was performed with in-hospital
mortality from any cause as the dependent factor and 22 inde-
pendent factors: age, sex, urgency of the operation, history of
cardiac surgery, concurrent cardiac or cardiovascular proce-
dures, left ventricular function, recent myocardial infarct, left
main coronary artery stenosis, chronic airways disease, cere-
brovascular disease, diabetes, hypertension, and other risk
factors including preoperative cardioactive drug use.
Stepwise regression was not used.
In this model we found the relative risk of mortality attrib-
utable to aprotinin to be 1.34 per million units of aprotinin
with 95% confidence intervals of 1.1 to 1.7 (P = .01 for rela-
tive risk = 1). This indicates a risk-adjusted association
between aprotinin and in-hospital mortality.
In the jargon of evidence-based medicine, our data are
“class III evidence” and should not be considered conclusive.
However, taken in conjunction with the IMAGE trial results,
our data support the hypothesis that in some circumstances
aprotinin may have a deleterious effect on patients undergo-
ing coronary artery operations.
We do not understand why aprotinin appears to have
adverse effects in some surgical units and not others. We use
balanced salt solutions for vein distention, maintain kaolin-
activated clotting times above 600 seconds, and never admin-
ister our blood cardioplegic solution through vein grafts.
Until it becomes clear why the adverse effects of aprotinin
appear to be site specific, we would suggest that aprotinin
should be used with caution in coronary artery operations.
William M. Weightman, MB, ChB
M. A. J. Newman, MD
Departments of Anesthesia and Cardiac Surgery
Sir Charles Gairdner Hospital
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Nedlands 6009, Australia
R E F E R E N C E S
1. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, et al.
Analyses of coronary graft patency after aprotinin use: results from
the International Multicenter Aprotinin Graft Patency Experience
(IMAGE) trial. J Thorac Cardiovasc Surg 1998;16:716-30.
2. Weightman WM, Gibbs NM, Sheminant MR, Whitford EG,
Mahon BD, Newman MAJ. Drug therapy before coronary artery
surgery: nitrates are independent predictors of mortality and beta
adrenergic blockers predict survival. Anesth Analg 1999;88:286-91.
12/8/101197
Reply to the Editor:
The letter by Weightman and Newman suggests a dose-
dependant mortality for aprotinin doses ranging from 0 to
‡ 4,000,000 KIU (see their Table I). In the IMAGE study (J
Thorac Cardiovasc Surg 1998;116:716-30), the average dose
in aprotinin-treated patients was 5,550,000 KIU (n = 436).
This total includes the 2,000,000 KIU loading dose,
2,000,000 KIU into the cardiopulmonary bypass circuit
prime, plus 1,570,000 KIU by continuous infusion at a pre-
scribed rate of 500,000 KIU per hour. IMAGE study results
showed that this administration regimen for aprotinin had no
effect on mortality (placebo, 1.6%; aprotinin, 1.4%). In the
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Table I. Dose of aprotinin, number of patients, and
in-hospital mortality rate for 1593 consecutive
patients undergoing coronary artery operations
Dose of aprotinin Mortality rate 
(106 KIU) n (%)
0 839 1.8
<1 248 3.2
1-1.9 191 3.1
2-2.9 201 6.5
3-3.9 62 9.7
‡ 4 52 11.5
